274 related articles for article (PubMed ID: 20072832)
1. Sunitinib.
Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib in the treatment of advanced solid tumors.
Imbulgoda A; Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2014; 201():165-84. PubMed ID: 24756791
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib in solid tumors.
Gan HK; Seruga B; Knox JJ
Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
6. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Polyzos A
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
8. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
9. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib.
Deeks ED; Keating GM
Drugs; 2006; 66(17):2255-66; discussion 2267-8. PubMed ID: 17137406
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
12. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
13. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
14. The potential role of sunitinib in gastrointestinal cancers other than GIST.
GrĂ¡valos C; Grande E; Gasent JM
Crit Rev Oncol Hematol; 2010 Oct; 76(1):36-43. PubMed ID: 20133148
[TBL] [Abstract][Full Text] [Related]
15. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Yuasa T; Takahashi S; Hatake K; Yonese J; Fukui I
Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity associated with sunitinib.
Hariharan S; Lowry S
Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
[No Abstract] [Full Text] [Related]
[Next] [New Search]